How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review
- PMID: 20043014
- DOI: 10.1038/jid.2009.391
How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review
Abstract
A large number of clinical measures of psoriasis are used in clinical trials and daily practice. These measures lack uniformity and validation. However, valid outcome and severity measures for psoriasis are a prerequisite for fully informative clinical research and evidence-based medicine. The purpose of this study was to identify all clinical measures of psoriasis severity and outcome in use and to evaluate the quality of these measures using clinimetric criteria; we identified 53 separate clinical measures, which were regrouped into 11 measures for quality analysis. No measure could be scored on all items used in the clinimetric analysis. The Lattice System Physician's Global Assessment and Physician's Global Assessment were most highly noted. We conclude that none of the psoriasis measures is adequately validated. The Psoriasis Area and Severity Index is the most commonly used clinical measure in research, but it has substantial limitations such as low response distribution, no consensus on interpretability, and low responsiveness in mild disease. Nevertheless, because of its widespread use the Psoriasis Area and Severity Index permits some degree of comparison of results among clinical trials. Overall, no best instrument was identified, and different situations may call for different measures.
Comment in
-
Validation of psoriasis clinical severity and outcome measures: searching for a gold standard.Arch Dermatol. 2011 Jan;147(1):95-8. doi: 10.1001/archdermatol.2010.242. Epub 2010 Sep 20. Arch Dermatol. 2011. PMID: 20855674 No abstract available.
Similar articles
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
-
Etanercept and efalizumab for the treatment of psoriasis: a systematic review.Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. doi: 10.3310/hta10460. Health Technol Assess. 2006. PMID: 17083854
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
Cited by
-
Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity.Qual Life Res. 2013 Nov;22(9):2489-99. doi: 10.1007/s11136-013-0384-y. Epub 2013 Mar 9. Qual Life Res. 2013. PMID: 23475691 Clinical Trial.
-
Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials.Br J Dermatol. 2022 Aug;187(2):203-210. doi: 10.1111/bjd.21236. Epub 2022 May 22. Br J Dermatol. 2022. PMID: 35599448 Free PMC article.
-
Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.Trials. 2021 Oct 16;22(1):707. doi: 10.1186/s13063-021-05681-z. Trials. 2021. PMID: 34656148 Free PMC article.
-
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.Dermatol Ther (Heidelb). 2022 Feb;12(2):495-510. doi: 10.1007/s13555-021-00649-y. Epub 2022 Jan 13. Dermatol Ther (Heidelb). 2022. PMID: 35025062 Free PMC article.
-
Disease severity and therapy as predictors of cardiovascular risk in psoriasis: a population-based cohort study.J Eur Acad Dermatol Venereol. 2012 Mar;26(3):336-43. doi: 10.1111/j.1468-3083.2011.04071.x. J Eur Acad Dermatol Venereol. 2012. PMID: 22339785 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous